Once a disease with poor outcomes, multiple myeloma now has new promise thanks to CAR T-cell therapy, which reprograms a patient’s immune cells to attack cancer. Some patients are experiencing ...

Each monthly installment examines an aspect of multiple myeloma care, including delivering the diagnosis, building trust, ...

Companies are adopting diverse approaches to reducing unwanted toxicities associated with cell and gene therapy.

Patients with multiple myeloma (MM) have a distinct pattern of second primary malignancy (SPM), with a markedly increased ...

Results from the MagnetisMM-5 study showed that Elrexfio significantly improved progression-free survival, which means ...

Cancer incidence is increasing, especially among younger adults, and current risk factors don’t fully account for the trend.

A new study has found that 11 types of cancer are on the rise in the 20 to 49-year-old age group, with obesity emerging as a ...

Pfizer said on Wednesday its drug Elrexfio met the main goal in a ​late-stage trial that tested the blood cancer ‌treatment ...

Topline data from the MagnetisMM-5 study demonstrate the superiority of elranatamab monotherapy over daratumumab plus pomalidomide and dexamethasone in double-class exposed multiple myeloma patients.

A new research paper was published in Volume 17 of Oncotarget on April 28, 2026, titled "Targeted therapeutics and U.S. population-level mortality trends in multiple myeloma: A SEER-based analysis ...

Pfizer (PFE) stock is in focus as a trial for the company's Elrexfio multiple myeloma drug hit the main goal with patients on ...